On Wednesday, Shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), gained 20.26% to $0.0926.
AEterna Zentaris declared recently that it has reached definitive agreements with the holders (the “Consenting Holders”) of about 90% of its outstanding Series B Common Share Purchase Warrants (the “Series B Warrants”) that are intended to reduce the dilutive effect of the exercise of the Series B Warrants by establishing a cap on the number of shares issuable upon alternate net cashless exercise (“Net Cashless Exercise”) of the Series B Warrants until the close of business on November 17, 2015 and by limiting the number of shares that the Consenting Holders may sell until the close of business on October 9, 2015. The Company was advised by Maxim Group LLC (“Maxim”) in its negotiations with the holders of the Series B Warrants. The effectiveness of the amendments to the Series B Warrants is subject to the approval of the Toronto Stock Exchange.
Under the terms of the agreements, the number of Common Shares issuable per Series B Warrant with respect to Net Cashless Exercises before the close of business on November 17, 2015 may not exceed 33.23 based on a floor on the average volume weighted average prices of $0.0541. The number of Common Shares issuable per Series B Warrant may be less than such number, however, if the price of the Company’s Common Shares recovers during the relevant period. In addition, during a trading-limitation period that expires at the close of business on October 9, 2015, the Consenting Holders have agreed to limit their market sales of our Common Shares to an aggregate of 100 million shares, which limitation shall not apply to any of the Company’s Common Shares sold at or above $0.10 per share.
As of September 21, 2015, about 10.8 million Series B Warrants remained outstanding, representing about 36% of the number originally issued. In addition, the Company anticipates that, as of the close business on September 21, 2015, there will be about 363.5 million issued and outstanding Common Shares.
Aeterna Zentaris Inc. is a Canada based biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology. The Company presently has three wholly owned direct and indirect auxiliaries, Aeterna Zentaris GmbH (AEZS Germany), Zentaris IVF GmbH, a wholly owned partner of AEZS Germany, and Aeterna Zentaris, Inc.
Shares of Dow Chemical Co (NYSE:DOW), declined -2.36% to $42.57, during its last trading session.
Working Mother magazine recently named Dow Chemical to the 2015 Working Mother 100 Best Companies list. This award honors companies that demonstrate commitment to progressive workplace programs, counting advancement of women, flexibility, child care and paid parental leave. Dow also declared recently its 2015 Working Mother of the Year, Mary Meyer. The Working Mother of the Year honor recognizes a working mom who succeeds in balancing work and family, serves as positive role model and mentor, and distinguishes herself in the community.
This year marks the third time in the award’s 30 year history that Dow has received this prestigious recognition from Working Mother. Dow and Meyer will be honored at the Working Mothers 100 Best Companies Work Life Congress on Oct. 14-15 at the New York Marriott Marquis in Times Square. Honorees will also attend the 100 Best Companies Gala Awards Dinner and take part in an awards presentation ceremony.
Dow’s 2015 Working Mother of the Year
Mary Meyer serves as Maintenance Group Leader for Plastics Central Maintenance at Dow Louisiana Operations. Meyer began her Dow career in 2006 as a maintenance and reliability engineer. Meyer lives in Brusly, La. with her husband, Justin, and they are the proud parents of four children. Beyond her professional role at Dow and her personal role as mother, Meyer is chairperson for the Louisiana Operations 2015 United Way Campaign, a Science Technology Engineering and Mathematics (STEM) ambassador, and a Women’s Innovation Network (WIN) steering team member. She is also an active member of St. John the Baptist Catholic Church.
The Dow Chemical Company (Dow) is as an integrated science and technology company. The Company is a diversified, manufacturer and supplier of products used primarily as raw materials in the manufacture of customer products and services across the world.
Shares of EMC Corporation (NYSE:EMC), inclined 0.25% to $23.82, during its last trading session.
EMC Corporation declared the appointment of Laura J. Sen (59) to the EMC Board of Directors, effective right away. Ms. Sen is presently Chief Executive Officer of BJ’s Wholesale Club. Her appointment expands the size of the EMC Board of Directors to thirteen.
Before her current role at BJ’s, Ms. Sen spent more than 20 years at BJ’s in a broad range of senior administration roles, counting President from January 2008 to September 2015, Chief Operating Officer from January 2008 to February 2009 and Executive Vice President of Merchandising and Logistics from January 2007 to January 2008.
EMC Corporation (EMC) is a service provider to information technology (IT) operations to an as a service model (ITaaS). It develops, delivers and supports the IT industry’s range of information infrastructure and virtual infrastructure technologies, solutions and services. EMC manages the Company as part of a federation of businesses: EMC Information Infrastructure, VMware Virtual Infrastructure and Pivotal. EMC Information Infrastructure business comprises of three divisons: Information Storage, Enterprise Content Division and RSA Information Security.
Finally, Intra-Cellular Therapies Inc (NASDAQ:ITCI), ended its last trade with 6.47% gain, and closed at $47.86.
Intra-Cellular Therapies declared the pricing of its formerly declared underwritten public offering of 6,900,000 shares of its common stock at a public offering price of $43.50 per share. All of the shares in the offering will be sold by Intra-Cellular Therapies. Net proceeds to Intra-Cellular Therapies from the sale of the shares, after deducting underwriting discounts and commissions and estimated offering expenses, are predictable to be about $284.7 million.
Intra-Cellular Therapies has granted the underwriters a 30-day option to purchase up to an additional 1,035,000 shares on the same terms and conditions. The predictable net proceeds to Intra-Cellular Therapies referenced above do not comprise any net proceeds that Intra-Cellular Therapies would receive if the underwriters exercise such option. The offering is predictable to close on September 28, 2015, subject to customary closing conditions. Leerink Partners LLC, Cowen and Company, LLC, RBC Capital Markets, LLC and Guggenheim Securities, LLC are acting as joint book-running managers for the offering. Ladenburg Thalmann & Co. Inc. and SunTrust Robinson Humphrey, Inc. are acting as co-managers.
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is developing its lead drug candidate, ITI-007, which is in Phase III clinical development as a treatment for schizophrenia. ITI-007 Program comprises ITI-007-005, which is in Phase II clinical trial, for the treatment in patients with an acutely exacerbated episode of schizophrenia, and ITI-007-200, which is in Phase I/II clinical trial, designed to evaluate the safety, tolerability and pharmacokinetics of low doses of ITI-007 in healthy geriatric subjects and in patients with dementia, counting Alzheimer’s disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
